FMP
2seventy bio, Inc.
TSVT
NASDAQ
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
4.96 USD
0 (0%)
Operating Data
Year
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Revenue
248.12M
54.52M
91.5M
100.39M
37.86M
31.92M
26.91M
22.69M
19.13M
16.12M
Revenue %
-
-78.03
67.81
9.72
-62.28
-15.69
-15.69
-15.69
-15.69
Ebitda
-131.45M
-297.16M
-251.38M
-206.42M
-98.45M
-28.92M
-24.38M
-20.55M
-17.33M
-14.61M
Ebitda %
-52.98
-545.03
-274.74
-205.62
-260.01
-90.6
-90.6
-90.6
-90.6
Ebit
-144.64M
-313.56M
-262.91M
-216.7M
-105.54M
-29.26M
-24.67M
-20.79M
-17.53M
-14.78M
Ebit %
-58.29
-575.11
-287.34
-215.87
-278.75
-91.66
-91.66
-91.66
-91.66
Depreciation
13.19M
16.4M
11.53M
10.29M
7.1M
4.91M
4.14M
3.49M
2.94M
2.48M
Depreciation %
5.32
30.08
12.6
10.25
18.74
15.4
15.4
15.4
15.4
Balance Sheet
Year
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Total Cash
-127.6M
362.18M
266.27M
216.99M
174.75M
22.25M
18.76M
15.82M
13.33M
11.24M
Total Cash %
-51.43
664.28
291.02
216.15
461.56
69.71
69.71
69.71
69.71
Receivables
10.69M
17M
20.96M
13.41M
-
4.58M
3.86M
3.26M
2.74M
2.31M
Receivables %
4.31
31.17
22.91
13.36
-
14.35
14.35
14.35
14.35
Inventories
127.6M
-114.12M
13.64M
-
-
-2.15M
-1.81M
-1.53M
-1.29M
-1.09M
Inventories %
51.43
-209.31
14.91
-
-
-6.73
-6.73
-6.73
-6.73
Payable
7.15M
6.02M
7.21M
6.03M
1.05M
1.95M
1.65M
1.39M
1.17M
986.82k
Payable %
2.88
11.05
7.88
6
2.79
6.12
6.12
6.12
6.12
Cap Ex
-22.26M
-19.57M
-22.84M
-13.87M
-707k
-5.46M
-4.6M
-3.88M
-3.27M
-2.76M
Cap Ex %
-8.97
-35.9
-24.97
-13.81
-1.87
-17.1
-17.1
-17.1
-17.1
Weighted Average Cost Of Capital
Price
4.96
Beta
Diluted Shares Outstanding
52.22M
Costof Debt
4.15
Tax Rate
After Tax Cost Of Debt
4.15
Risk Free Rate
Market Risk Premium
Cost Of Equity
Total Debt
243.72M
Total Equity
259M
Total Capital
502.72M
Debt Weighting
48.48
Equity Weighting
51.52
Wacc
6.68
Build Up Free Cash Flow
Year
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Revenue
248.12M
54.52M
91.5M
100.39M
37.86M
31.92M
26.91M
22.69M
19.13M
16.12M
Ebitda
-131.45M
-297.16M
-251.38M
-206.42M
-98.45M
-28.92M
-24.38M
-20.55M
-17.33M
-14.61M
Ebit
-144.64M
-313.56M
-262.91M
-216.7M
-105.54M
-29.26M
-24.67M
-20.79M
-17.53M
-14.78M
Tax Rate
-
-
-
-
-
-
-
-
-
-
Ebiat
-166.38M
-296.39M
-262.9M
-216.7M
-105.54M
-28.94M
-24.4M
-20.57M
-17.34M
-14.62M
Depreciation
13.19M
16.4M
11.53M
10.29M
7.1M
4.91M
4.14M
3.49M
2.94M
2.48M
Receivables
10.69M
17M
20.96M
13.41M
-
4.58M
3.86M
3.26M
2.74M
2.31M
Inventories
127.6M
-114.12M
13.64M
-
-
-2.15M
-1.81M
-1.53M
-1.29M
-1.09M
Payable
7.15M
6.02M
7.21M
6.03M
1.05M
1.95M
1.65M
1.39M
1.17M
986.82k
Cap Ex
-22.26M
-19.57M
-22.84M
-13.87M
-707k
-5.46M
-4.6M
-3.88M
-3.27M
-2.76M
Ufcf
-306.6M
-65.28M
-404.75M
-200.28M
-90.72M
-31.01M
-24.78M
-20.89M
-17.61M
-14.85M
Wacc
6.68
6.68
6.68
6.68
6.68
Pv Ufcf
-29.07M
-21.77M
-17.21M
-13.6M
-10.75M
Sum Pv Ufcf
-92.39M
Terminal Value
Growth In Perpetuity Method
Long Term Growth Rate
Wacc
6.68
Free Cash Flow T1
-15.14M
Terminal Value
-323.51M
Present Terminal Value
-234.13M
Intrinsic Value
Enterprise Value
-326.52M
Net Debt
172.47M
Equity Value
-498.99M
Diluted Shares Outstanding
52.22M
Equity Value Per Share
-9.56
Projected DCF
-9.56 1.519%
